Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $77.00 target price on the biotechnology company’s stock.

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock opened at $12.22 on Monday. The firm has a market cap of $555.64 million, a price-to-earnings ratio of -11.53 and a beta of 4.10. The stock’s 50-day moving average is $14.05 and its 200-day moving average is $14.50. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15. The firm had revenue of $11.13 million for the quarter, compared to analysts’ expectations of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. On average, equities analysts expect that Capricor Therapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. boosted its stake in shares of Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after buying an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in Capricor Therapeutics during the fourth quarter valued at approximately $68,000. AlphaQuest LLC bought a new position in Capricor Therapeutics in the fourth quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund increased its position in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 5,000 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.